Dr. Jeanmarie Guenot is an expert in managing and promoting companies in the fields of biotechnology and pharmaceuticals. She received her MBA from the Wharton School in Pennsylvania, and her Ph.D. from the University of California, in San Francisco. She currently serves as President and CEO of Amphivena Therapeutics. The company is involved in the development of bio-functional antibodies used in treating blood malignancies.
Jeanmarie Guenot started her career in science at Hoffmann-La Roche in research and development. According to linkedin.com, she was working to discover and develop drugs for autoimmune diseases, oncology, inflammation, and metabolic conditions. She used her training in medical and physical chemistry. Her work included finding methods for designing drugs, nuclear magnetic resonance and the refinement of X-rays.
Before joining Amphivena, Guenot built SKS Ocular. It was an ophthalmic company concentrating on treatments for ocular inflammation, macular degeneration and glaucoma therapeutics.
Jeanmarie Guenot was a business adviser to Hoffmann-La Roche in Shanghai and Basel early in her career. In 2005, she worked as Vice President of PDL BioPharma. She handled their acquisitions and mergers and licensing of their commercial products.
Dr. Guenot also works with Harpoon Therapeutics. She co-founded Maverick Therapeutics in 2016. They are a spin-off of Harpoon Therapeutics on crunchbase.com. She has been involved in the T-cell format of Maverick, which eliminates the toxicity in using T-cell radiation therapy on normal tissue. It is designed to remain inactive on administration, but becomes active in the environment of a tumor.
Jeanmarie Guenot, has over 20 years of experience in the pharmaceutical and biotech industries. She has worked in a variety of companies, from the development stages to well beyond. She has worked with both the public and private sectors at http://amphivena.com/amphivena_leaders/jeanmarie-guenot-ph-d/. Over the years, she has built and re-built companies with her vast knowledge of business and science. She continues to work to help develop more helpful drugs and medications for curing disease.
Malini Saba was born in Sri Lanka in Kuala Lumpur, Malaysia. Her middle class family first lived in Australia where Malini spent her childhood. She then got married and moved the United States at the age of 19. The young couple only had $200 to their name and had to find a way to survive. She and her former husband rented an apartment on the outskirts of Stanford University where they both pursued an education.
Life was not easy for the young couple. They lived in an apartment for 4 years, located by a railroad track, where trains shook their tiny abode every time they passed. Saba recalls how these struggles helped lay the foundation for her future achievements. Extremely interested in investments and the business world, Saba crashed gatherings of investment bankers and spent time talking and gathering information. She gained their advice on the money she had been saving and slowly started investing in real estate, commodities, and telecommunications.
Today, Malini Saba utilizes her self-made success to assist other women in following her path. Founder of the non-profit organization in 2001, “Street: Global Investments in Women”, Saba strives to change the way at-risk and low income women and children view themselves in our society. The fund also encourages investors to support gender diverse leadership roles. “Stree” gives women the opportunity to obtain healthcare, legal advice, and provides a platform for grassroots movements in countries like India, Africa, Central America, and Eastern Europe.
Malini Saba is currently one of the world’s top philanthropist and investors from South Asia. Saba holds the position of Chairman of Saban, an investment company that has world-wide interests in US technology companies, gas and oil properties in China, and deals in real estate in India and Australia. Having invested early in her career in Silicon Valley, Saba has invested in more than 20 companies in the technology field. Her investments have extended into Asia and South America as well. Her largest returns thus far have been from the oil and gas industries.
Saba’s philanthropy continues to thrive as in 2005, she donated $1 million towards the first Heart Research Center for the people of South Asia at El Camino Hospital in California. Her philanthropic efforts also included touring the areas in India and Sri Lanka that were hit by the 2004 tsunami. She donated $10 million to the victims of the natural disaster.